Researchers from the University of Warsaw (UW), as part of a consortium of Polish scientific institutions, will develop mRNA technology with high efficiency and application in anti-cancer therapies. 

The research project “Horizon of excellence in applications of matrix RNA in immuno-oncology [HERO]” was co-financed in the amount of almost PLN 70 million under the Virtual Research Institute (WIB) program. The research in the field of medical biotechnology – oncology is financed within WIB funds. The international panel of competition experts appreciated the scientific value of the project and its high commercialization potential.

The project will be implemented by a consortium of four Polish research units: the International Institute of Molecular and Cell Biology in Warsaw (research team leader unit), the University of Warsaw, the Institute of Physical Chemistry of the Polish Academy of Sciences and the Medical University of Warsaw.